C21 · Pharmaceuticals · Global
Radioligand therapy trial starts since 2023: Breast cancer
Global: 25 in 1 Jan 2023 to 27 Sep 2026.
- 25 Latest · Global · 1 Jan 2023 to 27 Sep 2026
- Irregular Release cadence
- 1 Record · 1 region · 2023–2026
Verified 27 Sep 2026 · 1 publisher
The figure
One published observation so far. A chart follows as soon as a second period is published.
Radioligand therapy trial starts since 2023: Breast cancer
Global, 1 Jan 2023 to 27 Sep 2026
Every record
1 record · 1 region · 2023–2026. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| Global 1 record | |||
| 1 Jan 2023 to 27 Sep 2026 | 25 | ClinicalTrials.gov · 27 Sep 2026 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Count of interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy whose conditions include breast cancer, started from 2023-01-01 to 2026-09-27.
- Measure
- One slice of Clinical trial starts ( basis: clinicaltrials gov registry, counting rule: by start date, form: count, segment: rlt breast ) . Total number of clinical trials initiated during a given period. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
Other slices of clinical trial starts
- Alzheimer's disease drug trial starts 21 clinicaltrials gov registry · by start date · alz
- Antibody-drug conjugate trial starts 21 clinicaltrials gov registry · by start date · adc
- Autoimmune cell therapy and T-cell engager trial starts 21 clinicaltrials gov registry · by start date · autoimmune
- Cardiometabolic RNA and next-generation lipid drug trial starts 21 clinicaltrials gov registry · by start date · rnacv
- GLP-1, incretin multi-agonist and amylin trial starts 21 clinicaltrials gov registry · by start date · glp1
- Gene editing trial starts 21 clinicaltrials gov registry · by start date · gene
- Inflammatory bowel disease drug trial starts 21 clinicaltrials gov registry · by start date · ibd
- KRAS and RAS inhibitor trial starts 21 clinicaltrials gov registry · by start date · kras
- Oncology bispecific antibody trial starts 21 clinicaltrials gov registry · by start date · bsab
- Radioligand therapy trial starts 21 clinicaltrials gov registry · by start date · rlt
- Phase I small molecule clinical trial share 6 phase 1 small molecule
- Large company small molecule share of Phase I clinical trial starts 4 large company phase 1 small molecule
Frequently asked questions
What is the latest radioligand therapy trial starts since 2023: Breast cancer?
Global: 25 in 1 Jan 2023 to 27 Sep 2026.
Where does this data come from?
From 1 document published by ClinicalTrials.gov. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Radioligand therapy trial starts since 2023: Breast cancer [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/ctgov-rlt-trial-starts-breast
"Radioligand therapy trial starts since 2023: Breast cancer." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-rlt-trial-starts-breast. Accessed 28 Oct. 2026.
StatOrigin. "Radioligand therapy trial starts since 2023: Breast cancer." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/ctgov-rlt-trial-starts-breast.
@misc{statorigin_ctgov_rlt_trial_starts_breast_2026, title = {Radioligand therapy trial starts since 2023: Breast cancer}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-rlt-trial-starts-breast}, note = {Data set. Accessed 2026-10-28} }